S&P 500   2,970.45 (+0.01%)
DOW   26,845.12 (+0.11%)
QQQ   191.44 (+0.17%)
AAPL   236.62 (+0.17%)
MSFT   139.90 (+0.16%)
AMZN   1,736.70 (+0.28%)
CGC   18.86 (-2.93%)
MU   44.89 (-0.47%)
GE   8.78 (-0.34%)
TSLA   256.77 (+3.58%)
AMD   30.50 (+2.52%)
T   37.43 (-0.43%)
NFLX   286.10 (+1.12%)
BAC   29.07 (+0.55%)
GILD   64.57 (+0.91%)
DIS   129.74 (-0.22%)
S&P 500   2,970.45 (+0.01%)
DOW   26,845.12 (+0.11%)
QQQ   191.44 (+0.17%)
AAPL   236.62 (+0.17%)
MSFT   139.90 (+0.16%)
AMZN   1,736.70 (+0.28%)
CGC   18.86 (-2.93%)
MU   44.89 (-0.47%)
GE   8.78 (-0.34%)
TSLA   256.77 (+3.58%)
AMD   30.50 (+2.52%)
T   37.43 (-0.43%)
NFLX   286.10 (+1.12%)
BAC   29.07 (+0.55%)
GILD   64.57 (+0.91%)
DIS   129.74 (-0.22%)
Log in

Novocure Stock Price, News & Analysis (NASDAQ:NVCR)

$76.72
-0.41 (-0.53 %)
(As of 10/14/2019 02:15 PM ET)
Today's Range
$76.29
Now: $76.72
$77.70
50-Day Range
$72.42
MA: $81.78
$97.33
52-Week Range
$26.02
Now: $76.72
$98.70
Volume210,820 shs
Average Volume669,885 shs
Market Capitalization$7.53 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.37
Novocure Ltd. is global oncology company, which engages in the development and commercialization of its innovative therapy. It focuses on the commercial adoption of Optune, and its Tumor Treating Fields delivery system, for the treatment of glioblastoma (GBM), and to advance programs testing the efficacy and safety of Optune in multiple solid tumor indications through clinical pipeline. Read More…

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:NVCR
CUSIPN/A
Phone44-0-15-3475-6700

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$248.07 million
Book Value$1.21 per share

Profitability

Net Income$-63,560,000.00

Miscellaneous

EmployeesN/A
Market Cap$7.53 billion
Next Earnings Date10/31/2019 (Confirmed)
OptionableOptionable

Receive NVCR News and Ratings via Email

Sign-up to receive the latest news and ratings for NVCR and its competitors with MarketBeat's FREE daily newsletter.


Novocure (NASDAQ:NVCR) Frequently Asked Questions

What is Novocure's stock symbol?

Novocure trades on the NASDAQ under the ticker symbol "NVCR."

How were Novocure's earnings last quarter?

Novocure Ltd (NASDAQ:NVCR) posted its quarterly earnings results on Thursday, July, 25th. The medical equipment provider reported ($0.01) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.07) by $0.06. The medical equipment provider earned $86.70 million during the quarter, compared to analysts' expectations of $78.98 million. Novocure had a negative return on equity of 31.80% and a negative net margin of 13.84%. The company's revenue was up 41.0% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.17) earnings per share. View Novocure's Earnings History.

When is Novocure's next earnings date?

Novocure is scheduled to release their next quarterly earnings announcement on Thursday, October 31st 2019. View Earnings Estimates for Novocure.

How can I listen to Novocure's earnings call?

Novocure will be holding an earnings conference call on Thursday, October 31st at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

What price target have analysts set for NVCR?

6 Wall Street analysts have issued 1-year price objectives for Novocure's shares. Their predictions range from $36.00 to $97.00. On average, they anticipate Novocure's stock price to reach $72.17 in the next year. This suggests that the stock has a possible downside of 6.0%. View Analyst Price Targets for Novocure.

What is the consensus analysts' recommendation for Novocure?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novocure in the last year. There are currently 3 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Novocure.

Has Novocure been receiving favorable news coverage?

Press coverage about NVCR stock has been trending negative recently, according to InfoTrie Sentiment Analysis. InfoTrie rates the sentiment of press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Novocure earned a coverage optimism score of -2.8 on InfoTrie's scale. They also gave media coverage about the medical equipment provider a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View News Stories for Novocure.

Are investors shorting Novocure?

Novocure saw a decline in short interest in the month of September. As of September 30th, there was short interest totalling 4,400,000 shares, a decline of 7.6% from the August 30th total of 4,760,000 shares. Based on an average daily trading volume, of 854,600 shares, the days-to-cover ratio is currently 5.1 days. Currently, 5.6% of the company's shares are sold short. View Novocure's Current Options Chain.

Who are some of Novocure's key competitors?

What other stocks do shareholders of Novocure own?

Who are Novocure's key executives?

Novocure's management team includes the folowing people:
  • Asaf Danziger, Chief Executive Officer & Director
  • Mike Ambrogi, Chief Operating Officer
  • Wilco Groenhuysen, CFO & Chief Accounting Officer
  • Eilon D. Kirson, Chief Science Officer, Head-Research & Development
  • Uri Weinberg, Vice President-Clinical Development

Who are Novocure's major shareholders?

Novocure's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Polianta Ltd (0.01%), Redhawk Wealth Advisors Inc. (0.01%), Crow Point Partners LLC (0.00%), Henry James International Management Inc. (0.00%) and Alpine Group USVI LLC (0.00%). Company insiders that own Novocure stock include Asaf Danziger, Charles G Phillips III, Eilon D Kirson, Gabriel Leung, Michael J Ambrogi, Pritesh Shah, Todd Christopher Longsworth, Wilhelmus Cm Groenhuysen, William F Doyle and Yoram Palti. View Institutional Ownership Trends for Novocure.

Which major investors are selling Novocure stock?

NVCR stock was sold by a variety of institutional investors in the last quarter, including Crow Point Partners LLC. Company insiders that have sold Novocure company stock in the last year include Asaf Danziger, Charles G Phillips III, Gabriel Leung, Michael J Ambrogi, Pritesh Shah, Todd Christopher Longsworth, Wilhelmus Cm Groenhuysen and William F Doyle. View Insider Buying and Selling for Novocure.

Which major investors are buying Novocure stock?

NVCR stock was purchased by a variety of institutional investors in the last quarter, including Polianta Ltd, Henry James International Management Inc., Alpine Group USVI LLC and Redhawk Wealth Advisors Inc.. View Insider Buying and Selling for Novocure.

How do I buy shares of Novocure?

Shares of NVCR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Novocure's stock price today?

One share of NVCR stock can currently be purchased for approximately $76.80.

How big of a company is Novocure?

Novocure has a market capitalization of $7.54 billion and generates $248.07 million in revenue each year. The medical equipment provider earns $-63,560,000.00 in net income (profit) each year or ($0.69) on an earnings per share basis. View Additional Information About Novocure.

What is Novocure's official website?

The official website for Novocure is http://www.novocure.com/.

How can I contact Novocure?

Novocure's mailing address is NO. 4 THE FORUM GRENVILLE STREET, ST. HELIER Y9, JE2 4UF. The medical equipment provider can be reached via phone at 44-0-15-3475-6700 or via email at [email protected]


MarketBeat Community Rating for Novocure (NASDAQ NVCR)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  378 (Thanks for Voting!)
Underperform Votes:  338 (Thanks for Voting!)
Total Votes:  716
MarketBeat's community ratings are surveys of what our community members think about Novocure and other stocks. Vote "Outperform" if you believe NVCR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVCR will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/14/2019 by MarketBeat.com Staff

Featured Article: What is a Roth IRA?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel